A New Oral Treatment For Type II Diabetes Mellitus

Status:
Completed

Trial end date:
2006-07-21

Target enrollment:

Participant gender:

This is a 24-week study investigating the safety and efficacy of several dosages of a potential new oral medicine for Type II diabetes mellitus.

Phase 2

GlaxoSmithKline